Transmission of *Babesia microti* Parasites by Solid Organ Transplantation

Meghan B. Brennan, Barbara L. Herwaldt, James J. Kazmierczak, John W. Weiss, Christina L. Klein, Catherine P. Leith, Rong He, Matthew J. Oberley, Laura Tonnetti, Patricia P. Wilkins, Gregory M. Gauthier

SYNOPSIS

Author affiliations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA (M.B. Brennan, J.W. Weiss, C.L. Klein, C.P. Leith, R. He, M.J. Oberley, G.M. Gauthier); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (B.L. Herwaldt, P.P. Wilkins); Wisconsin Division of Public Health, Madison (J.J. Kazmierczak); American Red Cross Badger–Hawkeye Blood Service Region, Madison (J.W. Weiss); American Red Cross Jerome H. Holland Laboratories for the Biomedical Sciences, Rockville, Maryland, USA (L. Tonnetti)

DOI: http://dx.doi.org/10.3201/eid2211.151028

This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 2034.

Release date: October 12, 2016; Expiration date: October 12, 2017

Learning Objectives

Upon completion of this activity, participants will be able to:

- Identify the presentation and likely mode of transmission of babesiosis after organ transplantation, based on 2 case reports
- Determine treatment of babesiosis in patients receiving organ transplantation
- Assess the clinical implications of findings from these case reports of babesiosis.

CME Editor

Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships: owns stock, stock options, or bonds from Pfizer.

Authors

Disclosures: Meghan B. Brennan, MD, MS; Barbara L. Herwaldt, MD, MPH; James J. Kazmierczak, DVM, MS; John W. Weiss, MD, PhD; Catherine P. Leith, MB BChir; Rong He, MD; Laura Tonnetti, PhD; Patricia P. Wilkins, PhD; and Gregory M. Gauthier, MD, MS, have disclosed no relevant financial relationships. Christina L. Klein, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Alexion Pharmaceuticals; served as a speaker or a member of a speakers bureau for Alexion Pharmaceuticals. Matthew J. Oberley, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Amgen; owns stock, stock options, or bonds from Novartis.
**SYNOPSIS**

*Babesia microti*, an intraerythrocytic parasite, is tickborne in nature. In contrast to transmission by blood transfusion, which has been well documented, transmission associated with solid organ transplantation has not been reported. We describe parasitologically confirmed cases of babesiosis diagnosed ≈8 weeks posttransplantation in 2 recipients of renal allografts from an organ donor who was multiply transfused on the day he died from traumatic injuries. The organ donor and recipients had no identified risk factors for tick-borne infection. Antibodies against *B. microti* parasites were not detected by serologic testing of archived pretransplant specimens. However, 1 of the organ donor’s blood donors was seropositive when tested postdonation and had risk factors for tick exposure. The organ donor probably served as a conduit of *Babesia* parasites from the seropositive blood donor to both kidney recipients. Babesiosis should be included in the differential diagnosis of unexplained fever and hemolytic anemia after blood transfusion or organ transplantation.

*B. microti*, an intraerythrocytic parasite, is the most common cause of human babesiosis in the United States and is endemic to the Northeast and upper Midwest regions, including parts of Wisconsin and Minnesota (1–4). *B. microti* infection can range from asymptomatic to severe. Common manifestations include hemolytic anemia and nonspecific influenza-like symptoms (2). Persons who are asplenic, elderly, or immunocompromised are at increased risk for symptomatic infection and for severe complications, such as multiorgan dysfunction and death (5).

The primary route of transmission of *B. microti* parasites is by the bite of an infected *Ixodes scapularis* tick (6). Transmission of *Babesia* parasites by blood transfusion also is well documented (7–11). In contrast, transmission associated with solid organ transplantation has not been reported. We investigated 2 cases of babesiosis for which transmission probably occurred when renal allografts were transplanted from a multiply transfused organ donor.

**Materials and Methods**

Diagnosis of babesiosis in 2 persons who received kidney transplants from the same donor prompted multifaceted, collaborative investigations, which were conducted by the authors and acknowledged persons and agencies (e.g., transplant, transfusion, and public health organizations). The Organ Procurement Organization (Madison, WI, USA) identified the disposition of all organs and tissues recovered from the organ donor and notified the United Network for Organ Sharing (Richmond, VA, USA) about the possibility of donor-derived transmission.

Only kidneys and corneas had been transplanted; the bilateral iliac arteries and veins had been recovered but discarded 14 days later, whereas the liver and other tissues that had been donated for research were embargoed. Medical and transfusion records of the organ donor and transplant recipients were reviewed, as were procedures and records for organ/tissue recovery, handling, and transplantation. The transplant recipients, the seropositive blood donor identified in the transfusion investigation, and surrogates for the organ donor were interviewed regarding risk factors for and potential clinical manifestations of *Babesia* infection.

Specimens from the transplant recipients, the organ donor, and the organ donor’s blood donors were tested for evidence of *Babesia* infection. Evaluations of the transplant recipients included light microscopy of Giemsa- or Wright-stained thick and thin blood smears for *Babesia* parasites. The Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) conducted reference diagnostic testing of specimens from transplant recipients and organ donor. CDC also conducted serologic testing by using an indirect fluorescent antibody (IFA) assay for total immunoglobulin against *B. microti* antigens (12). Serum and plasma specimens were tested in serial 4-fold dilutions, and a reciprocal dilution titer of 64 was considered positive. CDC conducted PCR analysis of whole-blood specimens from the transplant recipients by using primers specific for the *B. microti* 18S rRNA gene (13) and a previously described 2-step nested PCR (7). CDC also conducted *B. microti* PCR analysis of fresh-frozen hepatic tissue from the organ donor. No fresh-frozen renal tissue or whole-blood specimens from the organ donor were available for testing. However, paraffin-embedded, pretransplantation specimens from both kidneys were available and were tested by using a *B. microti* immunohistochemical (IHC) assay (14); CDC also conducted IHC testing of hepatic tissue.

The American Red Cross obtained blood/serum specimens from all 33 blood donors who had contributed components transfused into the organ donor. No segments or components from original donor units were available for testing. The American Red Cross tested postdonation specimens by using a *B. microti* IFA assay for IgG and a *B. microti* real-time PCR. IFA testing was conducted with serial 2-fold dilutions of samples.

**Case Reports**

**Renal Transplant Recipients**

In late August 2008, two men with end-stage diabetic nephropathy (a 65-year-old Wisconsin resident [patient A; the index case-patient] and a 41-year-old Iowa resident [patient B]) received renal allografts from the same deceased donor at the University of Wisconsin Hospital and Clinics (UWHC; Madison, WI, USA). Different surgeons in separate operating rooms transplanted the kidneys. Both patients received induction immunosuppressive therapy with basiliximab and maintenance therapy with prednisone, mycophenolate mofetil, and tacrolimus.
During the previous year and peritransplant period, neither patient lived or traveled in babesiosis-endemic regions, which in the Midwest, included parts of Minnesota and Wisconsin but not Iowa (Table), and they did not receive blood transfusions.

Both patients showed seroconversion and development of parasitologically confirmed cases of babesiosis, which were diagnosed ≈8 weeks posttransplantation (Table; Figure 1). At the request of the transplant physicians, both patients were evaluated by the same UWHC infectious disease specialists.

After babesiosis was diagnosed, doses of immunosuppressive medications were decreased and each patient received a 6-week course of oral antimicrobial drug therapy: atovaquone (750 mg, 2×/d for 6 wks) plus azithromycin (1,000 mg, 1×/d for 2 wks, followed by 600 mg, 1×/d for 4 wks). During therapy, symptoms resolved, laboratory parameters returned to reference ranges or values, and Babesia parasite DNA became undetectable (Table; Figure 1).

### Table. Characteristics of 2 patients who received renal allografts from the same organ donor and became infected with Babesia microti parasites, 2008*

| Characteristic                               | Patient A (index case-patient) | Patient B |
|----------------------------------------------|--------------------------------|-----------|
| Type of kidney transplant                    | Left                           | Right     |
| Age, ysex                                    | 65/M                           | 64/M      |
| Residence†                                   | Southcentral Wisconsin (urban, nonwooded area of Sauk County) | Iowa (seminal area bordering southwestern Wisconsin) |
| Cause of end-stage nephropathy               | Type 2 diabetes mellitus       | Type 1 diabetes mellitus |
| Pretransplant dialysis                        | Peritoneal dialysis in Wisconsin | Hemodialysis in Iowa |
| Other medical history                         | Diabetic retinopathy; coronary artery disease | Diabetic retinopathy (legally blind); hypertension |
| Duration of hospitalization for renal transplantation, d‡ | 6 (late Aug–early Sep)          | 10 (late Aug–early Sep; patient had moderate delay in graft function) |
| Clinical manifestations potentially attributable to babesiosis | Fever (39.4°C), sweats, fatigue, anorexia, dark urine | Fever (38°C), fatigue, abdominal pain |
| Babesia blood-smear examination              |                                 |           |
| Date of first positive blood smear           | Oct 20                         | Oct 23    |
| Initial parasitemia level, %                 | 8                              | 1         |
| Context for diagnosis                        | Platelet clumping prompted manual review of blood smear | Diagnosis of case in patient A prompted evaluation of patient B during a routine clinic visit |
| Date of last positive blood smear            | Oct 24                         | Oct 23    |
| Date of last B. microti PCR-positive blood specimen§ | Nov 7                          | Nov 21    |
| B. microti IFA titer (date)                  |                                 |           |
| Pretransplant serum sample                   | ≤8 (Jul 30)                    | ≤8 (Aug 11) |
| Posttransplant serum sample                  | 4,096 (Oct 21)                 | 1,024 (Oct 23) |
| Laboratory values when babesiosis was diagnosed (2, 6, and 16 wks after initiation of therapy)¶¶ |                                 |           |
| Hematocrit, %                                | 21 (21, 45, 49)                | 35 (41, 37, 44) |
| Reticulocyte, %                              | 11.7                           | 4.3       |
| Leukocyte count, x 10⁹/L**                   | 6.7                            | 5.5       |
| Platelet count, x 10⁹/L                      | 157                            | 154       |
| Haptoglobin, mg/dL                           | <8 (24, 67, 104)               | ND (154, 223, 202) |
| Lactate dehydrogenase, U/L                   | 747 (490, 220, ND)             | 495 (365, 344, 331) |
| Creatinine, mg/dL                            | 1.1                            | 1.3       |
| Dates of hospitalization for babesiosis      | Oct 20–24                      | None      |
| Dates of 6-wk course of azithromycin and atovaquone | Oct 20–Dec 1                   | Oct 23–Dec 4 |

*IFA, indirect fluorescent antibody; ND, not done.†Neither patient had lived or traveled in babesiosis-endemic areas in Wisconsin (primarily, the northwestern and northcentral regions) or elsewhere.‡Preparation of kidneys for transplantation included an in situ flush (initiated 25 min after the donor was declared brain dead and was exsanguinated) with 2 L of University of Wisconsin solution (15), each of which was infused in ≤4 min; a flush with 200 mL of this solution after the kidneys were explanted. §Both patients had negative PCR results for followup blood specimens in February 2009.¶Reference ranges: creatinine, 0.6–1.3 mg/dL; haptoglobin, 30–200 mg/dL; lactate dehydrogenase, 90–200 U/L.¶¶Hematocrit values posttransplantation were 37% (patient A) and 40% (patient B).**Different leukocyte counts were 73% neutrophils, 14% lymphocytes, and 13% monocytes for patient A; and 79% neutrophils, 12% lymphocytes, 8% monocytes, 1% eosinophils, and 1% basophils for patient B.

**Patient A**

On October 2, 2008 (~5 weeks posttransplantation), during a routine follow-up appointment at the UWHC Transplant Clinic, the wife of patient A mentioned that he had a lack of energy and decreased appetite (onset date not specified). At that clinic visit, his hematocrit was 37%, which approximated his baseline value posttransplantation.

On October 8, he was admitted to the UWHC, as planned, to have his peritoneal dialysis catheter removed the next day. However, at admission, he unexpectedly was found to have a temperature of 39.4°C. His hematocrit values were 33% and 28% on October 8 and 9, respectively. Removal of the catheter was postponed until October 10, and he was discharged after the procedure. Cultures of the
catheter tip, blood, and urine specimens were negative for bacterial growth. He was treated empirically with piperacillin/tazobactam during his 2-day hospitalization, followed by a 7-day outpatient course of ciprofloxacin.

On October 16 (day 6 of ciprofloxacin therapy), his wife called the transplant coordinator to report that he had a low-grade temperature (37.5°C) and a 2-day history of drenching sweats. An appointment in the Transplant Clinic was scheduled for October 20 to evaluate his symptoms. During the appointment, he reported a several-day history of darkening urine and progressive fatigue since his previous hospitalization. Per routine for clinic visits, a complete blood count was determined. His hematocrit had decreased to 21% (Table). Because platelet clumping was detected by using an automated hematology analyzer, a blood smear was reviewed manually: intraerythrocytic Babesia parasites were visualized at a parasitemia level of 8% (Table; Figure 2). On the same day (October 20), he was admitted to the UWHC, evaluated by the Infectious Disease Service, and began treatment with azithromycin plus atovaquone (Table; Figure 1). Within 48 hours of initiating therapy, his appetite and exercise tolerance increased, and his parasitemia level decreased to <5%.

**Organ Donor**

The organ donor was a 22-year-old man who was a resident of an urban area of Wisconsin to which babesiosis was not endemic. According to his relatives and primary care physician, he had been in good health and did not have any potentially relevant travel or clinical manifestations during the previous year. His only known risk factor for exposure to Babesia parasites was receipt of multiple blood transfusions during resuscitation attempts on the day he died from unintentional trauma. Although an autopsy was not performed, a limited number of plasma, serum, and tissue specimens were available for Babesia testing. Antibodies against B. microti parasites were not detected by retrospective serologic testing of a pretransfusion plasma specimen and 2 posttransfusion serum specimens (IFA titer ≤8). Tissue sections from...
both kidneys had negative IHC results. IHC testing of hepatic tissue showed a few rare foci of suspicious staining but no definitive evidence of 
Babesia parasites, and hepatic tissue showed negative results by PCR.

The cornea recipients were contacted, and blood specimens collected ≈3–4 months posttransplantation were tested for evidence of Babesia infection. Specimens showed negative results for PCR and IFA analysis, and no parasites were found on blood smears.

**Transfusion Investigation**

During resuscitation attempts, the organ donor received 20 cellular blood components (19 units of erythrocytes and 1 unit of apheresis platelets) and 13 plasma units. Only 1 of the 33 donors, a 52-year-old man, had evidence of 
B. microti infection. Specimens available for testing were collected 88 and 151 days postdonation and had IFA titers of 256 and 128, respectively; both specimens showed negative results by PCR. The seropositive blood donor was the source of 1 of the organ donor’s last erythrocyte transfusions, which was transfused 15 days postdonation.

This blood donor lived in a babesiosis-endemic area of Minnesota (Washington County) and had camped in disease-endemic areas in northern Wisconsin (Ashland County) in May 2008 and in northern Minnesota (Saint Louis County) in July 2008. During the retrospective investigation, he recalled a fever (39.4°C), chills, and diarrhea, which lasted ≈36 hours, during the first week of June. Although he did not recall any tick bites, his wife reportedly had found a tick on his body (timing and other details not specified). No cellular components from his donation in August were transfused to other patients. After he was found to be seropositive, he was deferred indefinitely from future blood donations. However, he already had donated blood in the interim (in September 2008), and apheresis platelets from the donation had been transfused. A specimen obtained ≈2 months posttransfusion from the platelet recipient was tested in a commercial laboratory and showed negative 
B. microti IFA and PCR results.

**Discussion**

We investigated parasitologically confirmed cases of babesiosis in 2 recipients of renal allografts from an organ donor whose only known risk factor for exposure to Babesia parasites was the receipt of multiple blood transfusions on the day he died. The organ donor and the kidney recipients did not have antibodies against 
B. microti parasites detected by retrospective testing of pretransplantation specimens. However, 1 of the organ donor’s blood donors was seropositive when tested postdonation and had risk factors for tick exposure.

The most likely scenario is that the kidney donor served as a conduit of Babesia parasites from this blood donor to the kidney recipients (i.e., the blood donor became infected by tickborne transmission, secondary transmission occurred by erythrocyte transfusion, and tertiary transmission occurred by organ transplantation). The possibility that the kidney recipients became infected independently is remote: they did not live, travel, or receive medical care in any known babesiosis-endemic areas in the Midwest or elsewhere; they did not receive any transfusions; and they showed seroconversion posttransplantation, despite being immunosuppressed. Although no subtyping tools are available to establish that the patients were infected with the same 
B. microti strain, they almost assuredly became infected from the same source at approximately the same time.

Previous reports have described organ transplant recipients who became infected with Babesia parasites by tickborne- or transfusion-associated transmission in the peritransplant period or thereafter (10,18–22). Transplantation-associated transmission of 
B. microti parasites, which are not known to have an eoxoerythrocytic tissue phase, has not been described, nor has the occurrence of 3 consecutive routes of transmission (vector, transfusion, and transplantation), which has been reported for West Nile virus (23,24). The plausibility of transplantation-associated transmission of 
B. microti parasites, in the context of residual parasites in the renal vasculature/fluids after...
illness in patient B was milder (lower-level parasitemia, minimal anemia, and transient fever) than that in patient A, even though the 2 patients received similar immunosuppressive regimens.

Babesiosis can be persistent, relapsing, or life threatening in immunocompromised patients (18,19,22,26–28). Optimal therapy for babesiosis in patients who have received an organ transplant or have impaired immunity for other reasons is not well established and might depend on multiple factors; a uniform recommendation might not be applicable to such a heterogeneous population. In immunocompetent persons, the typical duration of antimicrobial drug therapy for babesiosis is 7–10 days (6). We decided to treat both kidney recipients for 6 weeks on the basis of retrospective data for immunosuppressed patients that suggest the likelihood of cure is higher if combination antimicrobial drug therapy is administered for ≥6 weeks, including 2 weeks after Babesia parasites are no longer detected on blood smears (27). We gave the patients atovaquone plus azithromycin rather than clindamycin plus quinine (the standard of care for severely ill patients [6,29]) to minimize the likelihood of toxicity during their 6-week treatment courses. In addition, we decreased the doses of their immunosuppressive medications.

Both patients tolerated and responded well to the antimicrobial treatment, without documented relapses. However, clinicians should be aware that clinical resistance reportedly developed in several immunosuppressed patients treated for prolonged periods with atovaquone plus azithromycin (28); whether particulars of those patients’ treatment regimens (e.g., antimicrobial drug dosing) contributed to development of clinical resistance is not known (28,30).

The cases of babesiosis we describe not only underscore the plausibility and likelihood of transmission by organ transplantation, but also highlight the emerging role of transfusion-associated babesiosis. For the 3-decade period of 1979 (the year the first known transfusion case occurred) through 2009, a total of 159 transfusion-associated cases of B. microti infection were identified in the United States, most (77%) of which occurred during 2000–2009 (10). Asymptomatic persons can fulfill all of the criteria for donating blood despite having low-level parasitemia sufficient to cause infection in a transfusion recipient (10).

To date, no Babesia tests for screening US blood donors have been licensed by the Food and Drug Administration, and no pathogen-reduction technologies for cellular blood components have been approved (31–35). However, the Blood Products Advisory Committee of the Food and Drug Administration that was convened on May 13, 2015, supported the concepts of year-round B. microti serologic testing of all US blood donors and of B. microti nucleic acid–based testing of donors in selected states (details remain to be determined) (36). Because of donor travels and shipments/distributions of blood
components, transmission by transfusion is not limited to babesiosis-endemic foci (70). For example, the seropositive erythrocyte donor we identified had donated blood in a babesiosis-endemic area of Minnesota. This blood was then transported to and transfused in an area of Wisconsin to which babesiosis was not endemic.

As we described, unrecognized tickborne transmission of Babesia parasites to the blood donor probably led to transmission by transfusion to the organ donor and subsequent transmission by organ transplantation to both kidney recipients. Clinicians should include babesiosis in the differential diagnosis of unexplained fever and hemolytic anemia after blood transfusion or organ transplantation, even in regions to which babesiosis is not endemic. Suspected cases of iatrogenic transmission should be reported to state and local public health authorities. In addition, cases that might be transfusion or transplantation associated should be reported to the pertinent blood center and organ procurement organization, respectively.

Acknowledgments

We thank the many persons who contributed to the collaborative investigations, including contributors at the American Red Cross, the Centers for Disease Control and Prevention, the Lions Eye Bank of Wisconsin, the Musculoskeletal Transplant Foundation, the University of Wisconsin Hospital and Clinics, the University of Wisconsin Organ and Tissue Donation, and public health departments in Wisconsin and Minnesota, as well as other health professionals. We also thank the kidney and cornea recipients, the seropositive blood donor, the family of the organ donor, and the healthcare providers of the recipients and donors.

This work was supported by grants (U1LTR000427 and KL2TR000428) from the National Institutes of Health to the Wisconsin Institute for Clinical and Translational Research.

Dr. Brennan is an infectious disease physician at the University of Wisconsin Hospital and Clinics, Madison, Wisconsin. Her primary research interest is infectious disease health services.

References

1. Pfeiffer CD, Kazmierczak JJ, Davis JP. Epidemiologic features of human babesiosis in Wisconsin, 1996–2005. WMJ. 2007;106:191–5.
2. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366:2397–407. http://dx.doi.org/10.1056/NEJMr1202018
3. Herwaldt BL, Montgomery S, Woodhall D, Bosserman EA; Centers for Disease Control and Prevention (CDC). Babesiosis surveillance—18 states, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:505–9.
4. Kowalski TJ, Jobe DA, Dolan EC, Kessler A, Lovrich SD, Callister SM. The emergence of clinically relevant babesiosis in southwestern Wisconsin. WMJ. 2015;114:152–7.
5. Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis. 2001;32:1117–25. http://dx.doi.org/10.1086/319742
6. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134. http://dx.doi.org/10.1086/508667
7. Herwaldt BL, Neitzel DF, Gorlin JB, Jensen KA, Perry EH, Peglow WR, et al. Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6-month period. Transfusion. 2002;42:1154–8. http://dx.doi.org/10.1046/j.1537-2995.2002.00189.x
8. Tonnetti L, Eder AF, Dy B, Kennedy J, Pisciotto P, Benjamin RJ, et al. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion. 2009;49:2557–63. http://dx.doi.org/10.1111/j.1537-2995.2009.02317.x
9. Asad S, Sweeney J, Mermel LA. Transfusion-transmitted babesiosis in Rhode Island. Transfusion. 2009;49:2564–73. http://dx.doi.org/10.1111/j.1537-2995.2009.02380.x
10. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011;155:509–19. http://dx.doi.org/10.7263/0003-4819-155-8-201110180-00036
11. Leiby DA. Transfusion-transmitted Babesia spp.: bull’s-eye on Babesia microti. Clin Microbiol Rev. 2011;24:14–28. http://dx.doi.org/10.1128/CMR.00022-10
12. Chisholm ES, Ruebush TK II, Sulzer AJ, Healy GR. Babesia microti infection in man: evaluation of an indirect immunofluorescent antibody test. Am J Trop Med Hyg. 1978;27:14–9.
13. Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, et al. Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol. 1992;30:2097–103.
14. Torres-Vélez FJ, Nace EK, Won KY, Bartlett J, Eberhard M, Guerner J. Development of an immunohistochemical assay for the detection of babesiosis in formalin-fixed, paraffin-embedded tissue samples. Am J Clin Pathol. 2012;130:833–8. http://dx.doi.org/10.1309/UXP8HRJ2EPRUCP1N
15. Belzer FO, D’Alessandro AM, Hoffmann RM, Knechtle SJ, Reed A, Pirsch JD, et al. The use of UW solution in clinical transplantation: a 4-year experience. Ann Surg. 1992;215:579–83, discussion 584–5. http://dx.doi.org/10.1097/00000658-199206000-00004
16. Florescu D, Sordillo PP, Gympis A, Zlatanice E, Smith B, Polsky B, et al. Splenic infarction in human babesiosis: two cases and discussion. Clin Infect Dis. 2008;46:e8–11. http://dx.doi.org/10.1086/524081
17. El Khoury MY, Gandhi R, Dandache P, Lombardo G, Wormser GP. Pancytopenia due to hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation. 2000;70:804–5. http://dx.doi.org/10.1097/00007890-199206000-00004
18. Gupta P, Hurley RW, Helseth PH, Goodman JL, Hammerschmidt DE. Non-surgical management of spontaneous splenic rupture due to Babesia microti infection. Ticks Tick Borne Dis. 2011;2:235–8. http://dx.doi.org/10.1016/j.ttbdis.2011.08.001
19. Gupta P, Hurley RW, Helseth PH, Goodman JL, Hammerschmidt DE. Pancytopenia due to hemophagocytic syndrome as the presenting manifestation of babesiosis. Am J Hematol. 1995;50:60–2. http://dx.doi.org/10.1002/ajh.2830500113
20. Slovut DP, Benedetti E, Matas AJ. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation. 1996;62:537–9. http://dx.doi.org/10.1097/00007890-199608090-00018
21. Evenson DA, Perry E, Kloster B, Hurley R, Stroncek DF. Therapeutic apheresis for babesiosis. J Clin Apher. 1998;13:32–6. http://dx.doi.org/10.1002/ajh.2830500113
22. Perdrizet GA, Olson NH, Krause PJ, Banevert GT, Spielman A, Cable RG. Babesiosis in a renal transplant recipient acquired through blood transfusion. Transplantation. 2000;70:205–8.
SYNOPSIS

Emerg Infect Dis. 2003;9:116–9. http://dx.doi.org/10.3201/eid0901.020149

23. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellingier WC, et al.; West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348:2196–203. http://dx.doi.org/10.1056/NEJMoa022987

24. Stanley E, Ratard R, Staples JE, Royce R, Bower WA, Ellingson KD, et al.; Centers for Disease Control and Prevention (CDC). West Nile virus transmission via organ transplantation and blood transfusion—Louisiana, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1263–7.

25. Etkind P, Piesman J, Ruebush TK II, Spielman A, Juranek DD. Methods for detecting Babesia microti infection in wild rodents. J Parasitol. 1980;66:107–10. http://dx.doi.org/10.2307/3280599

26. Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis. 2007;45:1588–90. http://dx.doi.org/10.1086/525731

27. Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46:370–6. http://dx.doi.org/10.1086/525852

28. Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010;50:381–6. http://dx.doi.org/10.1086/649859

29. Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, Telford SR III, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454–8. http://dx.doi.org/10.1086/301449

30. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767–77. http://dx.doi.org/10.1001/jama.2016.2884

31. Leiby DA, Johnson ST, Won KY, Nace EK, Slemenda SB, Pieniazek NJ, et al. A longitudinal study of Babesia microti infection in seropositive blood donors. Transfusion. 2014;54:2217–25. http://dx.doi.org/10.1111/trf.12622

32. Leiby DA. Transfusion-associated babesiosis: shouldn’t we be ticked off? Ann Intern Med. 2011;155:556–7. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00363

33. Gubernot DM, Nakhasi HL, Mied PA, Ascher DM, Epstein JS, Kumar S. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion. 2009;49:2759–71. http://dx.doi.org/10.1111/j.1537-2995.2009.02429.x

34. AABB. Babesiosis. Association Bulletin #14–05. 2014 July 18 [cited 2016 Mar 20]. http://www.aabb.org/programs/publications/bulletins/Documents/ab14-05.pdf.

35. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply—time to raise the bar. N Engl J Med. 2015;372:1882–5. http://dx.doi.org/10.1056/NEJMp1500154

36. Food and Drug Administration. Meeting of the Blood Products Advisory Committee. Strategies for implementation of antibody and nucleic acid-based testing for Babesia microti in blood donors, May 13, 2015 [cited 2016 Mar 20]. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm441228.htm

Address for correspondence: Meghan B. Brennan, University of Wisconsin Medical Foundation Centennial Bldg, 5th Fl, 1685 Highland Ave, Madison, WI 53705, USA; email: mbrennan@medicine.wisc.edu

World Pneumonia Day, November 12

Established in 2009, World Pneumonia Day is marked every year on November 12 to:

- Raise awareness about pneumonia, the world’s leading killer of children under the age of five;
- Promote interventions to protect against, prevent and treat pneumonia; and
- Generate action to combat pneumonia.

Pneumonia is one of the most solvable problems in global health, yet a child dies from the infection every 20 seconds.

http://wwwnc.cdc.gov/eid/page/world-pneumonia-day

World Pneumonia Day, November 12

Established in 2009, World Pneumonia Day is marked every year on November 12 to:

- Raise awareness about pneumonia, the world’s leading killer of children under the age of five;
- Promote interventions to protect against, prevent and treat pneumonia; and
- Generate action to combat pneumonia.

Pneumonia is one of the most solvable problems in global health, yet a child dies from the infection every 20 seconds.

http://wwwnc.cdc.gov/eid/page/world-pneumonia-day